Novartis Sees Clear Opportunity in Encore Vision’s Unique Approach to Correcting Presbyopia

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 119″]

Frederic Guerard, head of Novartis’ ophthalmology franchise, explains why the global giant was the last strategic standing in the competitive bidding to acquire the promising, but very early stage, start-up. Novartis will resume testing of the new presbyopia-correcting ophthalmic solution, now dubbed UNR-844.

Podcast Guest:

Frederic-Guerard

Frederic Guerard

Frederic Guerard is the Worldwide Business Franchise Head, Ophthalmology for Novartis after having served as Global Business Franchise Head Pharmaceuticals for Alcon.

View Full Profile